Literature DB >> 11126333

Serum concentrations of TNF-alpha and soluble TNF-alpha receptors in obesity.

B Zahorska-Markiewicz1, J Janowska, M Olszanecka-Glinianowicz, A Zurakowski.   

Abstract

OBJECTIVE: To study whether weight reducing treatment modulates serum concentration of TNF-alpha and two soluble TNF-alpha receptors in obese subjects. SUBJECTS AND MEASUREMENTS: Serum concentrations of TNF-alpha and two soluble receptors (sTNF-R1, sTNF-R2), plasma glucose, insulin, total cholesterol, HDL-cholesterol and triglicerides were measured in 27 obese subjects (age 48 +/- 12y, body mass index (BMI): 36 +/- 6 kg/m2) before and after 3 months weight reducing treatment consisted of a diet & 1,000 kcal/day and physical exercises.
RESULTS: The mean loss of weight during 3 months' treatment was 9.3 +/- 3.3 kg. The serum concentration of TNF-alpha decreased after weight loss and at the same time both of the receptors (sTNF-R1,sTNF-R2) increased significantly.
CONCLUSION: The observed decrease of the serum concentration of TNF-alpha and the increase in both TNF soluble receptors after weight reducing treatment in obese subjects, may be a counter-regulation preventing further weight loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126333     DOI: 10.1038/sj.ijo.0801398

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  33 in total

1.  The role of the gut microbiota in nonalcoholic fatty liver disease.

Authors:  Ahmed Abu-Shanab; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

2.  Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population?

Authors:  Núria Vilarrasa; Joan Vendrell; Javier Maravall; Iñaki Elío; Esther Solano; Patricia San José; Isabel García; Núria Virgili; Juan Soler; José Manuel Gómez
Journal:  Endocrine       Date:  2010-07-23       Impact factor: 3.633

3.  CRP, but not TNF-α or IL-6, decreases after weight loss in patients with morbid obesity exposed to intensive weight reduction and balneological treatment.

Authors:  Danuta Rość; Przemysław Adamczyk; Joanna Boinska; Robert Szafkowski; Irena Ponikowska; Katarzyna Stankowska; Barbara Góralczyk; Barbara Ruszkowska-Ciastek
Journal:  J Zhejiang Univ Sci B       Date:  2015-05       Impact factor: 3.066

Review 4.  Inflammation and insulin resistance: New targets encourage new thinking: Galectin-3 and LTB4 are pro-inflammatory molecules that can be targeted to restore insulin sensitivity.

Authors:  Andrew M F Johnson; Shaocong Hou; Pingping Li
Journal:  Bioessays       Date:  2017-07-28       Impact factor: 4.345

5.  Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

Authors:  Undurti N Das
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-02       Impact factor: 5.555

Review 6.  A narrative review of the associations between six bioactive components in breast milk and infant adiposity.

Authors:  David A Fields; Camille R Schneider; Gregory Pavela
Journal:  Obesity (Silver Spring)       Date:  2016-05-06       Impact factor: 5.002

Review 7.  Biomarkers of obesity and subsequent cardiovascular events.

Authors:  Salma Musaad; Erin N Haynes
Journal:  Epidemiol Rev       Date:  2007-05-10       Impact factor: 6.222

Review 8.  TNF-alpha and adipocyte biology.

Authors:  William P Cawthorn; Jaswinder K Sethi
Journal:  FEBS Lett       Date:  2007-11-26       Impact factor: 4.124

9.  Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy.

Authors:  Dawn Wiese; Bret Lashner; Douglas Seidner
Journal:  Nutr Clin Pract       Date:  2008 Oct-Nov       Impact factor: 3.080

10.  Is chronic inflammation a possible cause of obesity-related depression?

Authors:  Magdalena Olszanecka-Glinianowicz; Barbara Zahorska-Markiewicz; Piotr Kocełak; Joanna Janowska; Elzbieta Semik-Grabarczyk; Tomasz Wikarek; Wojciech Gruszka; Piotr Dabrowski
Journal:  Mediators Inflamm       Date:  2009-06-29       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.